AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3693807 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (beta-adrenergic blocker)
Number of subjects: 10
Study 3693807 — intervention group
Group type: COMPARATOR
Intervention: Placebo (untreated eyes)
Number of subjects: 10
Study 2717098 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 0
Study 2717098 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30946463 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated Forgetting (MF) condition
Number of subjects: 0
Study 30946463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap group in MF condition
Number of subjects: 0
Study 30946463 — intervention group
Group type: EXPERIMENTAL
Intervention: No-think words recall performance
Number of subjects: 0
Study 30946463 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 29354912 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus electroacupuncture (EA)
Number of subjects: 60
Study 29354912 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study 26174232 — intervention group
Group type: EXPERIMENTAL
Intervention: UPS+TFS fixation
Number of subjects: 40
Study 26174232 — intervention group
Group type: COMPARATOR
Intervention: BPS fixation
Number of subjects: 40
Study 24231454 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT11), fluorouracil and leucovorin (IFL)
Number of subjects: 627
Study 24231454 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil and leucovorin (FU/LV)
Number of subjects: 627
Study 24231454 — intervention group
Group type: EXPERIMENTAL
Intervention: PIK3CA mutation status
Number of subjects: 627
Study 21941005 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation (CrMS)
Number of subjects: 8
Study 21941005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18363758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied twice daily for 2 weeks, then to both sides for 6 weeks
Number of subjects: 18
Study 18363758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied to L-sides after initial treatment on P-sides
Number of subjects: 18
Study 18363758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied to P-sides
Number of subjects: 18
Study 18363758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied to L-sides
Number of subjects: 18
Study 16597037 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 52
Study 16597037 — intervention group
Group type: COMPARATOR
Intervention: Routine methods (psychotherapy, daub narcotic to glans of penis, and medication for chronic prostatitis)
Number of subjects: 52
Study 14678093 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (12 g orally daily for up to 5 days)
Number of subjects: 0
Study 14678093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14678093 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 0
Study 11305512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouchitis patients (n = 9)
Number of subjects: 9
Study 11305512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouchitis patients (n = 25)
Number of subjects: 9
Study 11305512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouchitis patients (n = 15)
Number of subjects: 9
Study 11305512 — intervention group
Group type: COMPARATOR
Intervention: Non-pouchitis patients (n = 10)
Number of subjects: 9
Study 11305512 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (n = 9)
Number of subjects: 9
Study 9128305 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrett's esophagus group
Number of subjects: 79
Study 9128305 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 79
Study 7898065 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 7898065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3594133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue biological adhesive system (BAS) applied in Group I (42 patients)
Number of subjects: 112
Study 3594133 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II, 70 patients)
Number of subjects: 112
Study 31578136 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc bisglycinate (15 mg elemental zinc)
Number of subjects: 86
Study 29482636 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based Face-to-face (n=70; six group sessions led by a psychologist)
Number of subjects: 219
Study 29482636 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based Mobile (n=78; one group session and mobile app)
Number of subjects: 219
Study 29482636 — intervention group
Group type: COMPARATOR
Intervention: Control (n=71; only the measurements)
Number of subjects: 219
Study 27485028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 3 mg
Number of subjects: 40
Study 27485028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 6 mg
Number of subjects: 40
Study 27485028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 12 mg
Number of subjects: 40
Study 27485028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 24 mg
Number of subjects: 40
Study 27485028 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 27485028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone with RU486 (GR antagonist)
Number of subjects: 40
Study 24999075 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (LNG-IUD)
Number of subjects: 165
Study 24999075 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (LNG-IUD) + metformin
Number of subjects: 165
Study 24999075 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (LNG-IUD) + weight loss intervention
Number of subjects: 165
Study 24999075 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study 22651256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 86
Study 22651256 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 86
Study 22651256 — intervention group
Group type: EXPERIMENTAL
Intervention: siRNA-mediated knockdown of SUMO-1
Number of subjects: 86
Study 20881062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula (28-43% more protein and 6-12% more energy than control formula)
Number of subjects: 243
Study 20881062 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 243
Study 18390077 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg of vaginal misoprostol
Number of subjects: 113
Study 16183363 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-based intervention (face-to-face counseling session, phone call, and three mailings) for 3 months
Number of subjects: 0
Study 16183363 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control period)
Number of subjects: 0
Study 12586677 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta
Number of subjects: 0
Study 12586677 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer
Number of subjects: 0
Study 11742882 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC10A2 gene analysis in hypertriglyceridemic patients
Number of subjects: 20
Study 11742882 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (unaffected)
Number of subjects: 20
Study 11742882 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfected COS cells with SLC10A2 mutations
Number of subjects: 20
Study 9240105 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with poorer health status (RR = 2.39; 95% CI = 1.86, 3.07)
Number of subjects: 0
Study 9240105 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with asthma (RR = 2.24; CI = 1.31, 3.80)
Number of subjects: 0
Study 9240105 — intervention group
Group type: EXPERIMENTAL
Intervention: Women reporting poorer health status (1 year, RR = 3.17; CI = 2.04, 4.94; > 1 year, RR = 8.42; CI = 2.20, 12.88)
Number of subjects: 0
Study 9240105 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with more than 1 year of poverty (RR = 3.28; CI = 1.90, 5.66)
Number of subjects: 0
Study 9240105 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with obesity (RR = 3.30; CI = 1.44, 7.55)
Number of subjects: 0
Study 9240105 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with more than 1 year of employment (RR = 0.55; CI = 0.36, 0.86)
Number of subjects: 0
Study 8215491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine, 2.5 mg/kg per day
Number of subjects: 40
Study 8215491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8215491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine, 1.25 mg/kg per day
Number of subjects: 40
Study 8215491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine, 3.75 mg/kg per day
Number of subjects: 40
Study 3317328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid administered once daily, 1/2 to 1 hour before surgery, continued for up to 72 hours.
Number of subjects: 117
Study 3317328 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin administered every eight hours, 1/2 to 1 hour before surgery, continued for up to 72 hours.
Number of subjects: 117
Study 3317328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid and Cefazolin (both interventions).
Number of subjects: 117
Study 31804741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg intravenous, administered two weeks apart
Number of subjects: 11
Study 31804741 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid therapy
Number of subjects: 11
Study 31615573 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-based HSCP assessment and intervention
Number of subjects: 320
Study 31615573 — intervention group
Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 320
Study 28444779 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 123
Study 28444779 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone and desflurane
Number of subjects: 123
Study 25566763 — intervention group
Group type: EXPERIMENTAL
Intervention: Masivukeni intervention
Number of subjects: 55
Study 25566763 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) counseling
Number of subjects: 55
Study 23975945 — intervention group
Group type: EXPERIMENTAL
Intervention: PHD testing without anesthesia
Number of subjects: 44
Study 23975945 — intervention group
Group type: COMPARATOR
Intervention: PHD testing with anesthesia
Number of subjects: 44
Study 21406695 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxidized aqueous solution
Number of subjects: 20
Study 21406695 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study 18982248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet administered 45 min before food (pre-feed)
Number of subjects: 10
Study 18982248 — intervention group
Group type: COMPARATOR
Intervention: Tablet administered on an empty stomach (fasted)
Number of subjects: 10
Study 18982248 — intervention group
Group type: COMPARATOR
Intervention: Tablet administered after food (fed)
Number of subjects: 10
Study 18982248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet administered pre-feed (in six volunteers)
Number of subjects: 10
Study 17870483 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage pain protocol
Number of subjects: 800
Study 17870483 — intervention group
Group type: COMPARATOR
Intervention: Standard care (prior to protocol)
Number of subjects: 800
Study 14998240 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious Cognitive Arousal Group
Number of subjects: 54
Study 14998240 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral Cognitive Arousal Group
Number of subjects: 54
Study 14998240 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious Cognitive Arousal
Number of subjects: 54
Study 14998240 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological Arousal
Number of subjects: 54
Study 14998240 — intervention group
Group type: COMPARATOR
Intervention: No manipulation
Number of subjects: 54
Study 11290851 — intervention group
Group type: EXPERIMENTAL
Intervention: High school-based alcohol prevention program (n = 1,820)
Number of subjects: 4635
Study 11290851 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 2,815)
Number of subjects: 4635
Study 9589652 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.1 mg/kg.day)
Number of subjects: 17
Study 8061799 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 38
Study 2648916 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 36
Study 2648916 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 36
Study 31241194 — intervention group
Group type: EXPERIMENTAL
Intervention: NO‐ASPIRATE
Number of subjects: 513
Study 31241194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 513
Study 27214600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low demands
Number of subjects: 80
Study 27214600 — intervention group
Group type: EXPERIMENTAL
Intervention: High demands
Number of subjects: 80
Study 27214600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low decision latitude
Number of subjects: 80
Study 27214600 — intervention group
Group type: EXPERIMENTAL
Intervention: High decision latitude
Number of subjects: 80
Study 25271207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 70
Study 25271207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23485096 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise
Number of subjects: 81
Study 23485096 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 81
Study 21685437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 5216
Study 21685437 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 5216
Study 19436670 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg once daily, increased to 16 mg if BP not normalized, with possible addition of hydrochlorothiazide 12.5 mg
Number of subjects: 209
Study 19436670 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate (AML) 5 mg once daily, increased to 10 mg if BP not normalized, with possible addition of hydrochlorothiazide 12.5 mg
Number of subjects: 209
Study 16393744 — intervention group
Group type: COMPARATOR
Intervention: Slow-release oral morphine
Number of subjects: 240
Study 16393744 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 240
Study 16393744 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 240
Study 16393744 — intervention group
Group type: COMPARATOR
Intervention: Opioid clients at admission
Number of subjects: 240
Study 15196586 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin IR tablet (500 mg)
Number of subjects: 12
Study 11417922 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 17
Study 11417922 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitemporal treatment (after right unilateral treatment failure)
Number of subjects: 17
Study 9165286 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled hand washing (minimum of four times a day)
Number of subjects: 305
Study 9165286 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual hand washing practices)
Number of subjects: 305
Study 8544367 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression-dependent trait group
Number of subjects: 62
Study 8544367 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression-independent trait group
Number of subjects: 62
Study 8544367 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 62
Study 2320205 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy for newly diagnosed malignant astrocytoma (Group I)
Number of subjects: 46
Study 2320205 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy for recurrent malignant astrocytoma (Group II)
Number of subjects: 46
Study 2320205 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy for recurrent solitary cerebral metastasis (Group III)
Number of subjects: 46
Study 2320205 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy overall
Number of subjects: 46
Study 2320205 — intervention group
Group type: EXPERIMENTAL
Intervention: Second operation for clinical and radiological deterioration
Number of subjects: 46
Study 444956 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg thrice daily for seven days)
Number of subjects: 7
Study 444956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for three to seven days)
Number of subjects: 7
Study 31029148 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel methods for monitoring and managing data return rates, including an automated database report and a Microsoft Excel-based tool.
Number of subjects: 669
Study 31029148 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacting centres regarding falling data return rates.
Number of subjects: 669
Study 27760719 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen (FB)
Number of subjects: 275
Study 27760719 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 275
Study 27760719 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cell count (WBC)
Number of subjects: 275
Study 27760719 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute neutrophil count (ANC)
Number of subjects: 275
Study 26004173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 28
Study 26004173 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary Occlusal Splint (MOS)
Number of subjects: 28
Study 26004173 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 28
Study 25240012 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine intracervical injection 5 min prior to LNG-IUS insertion
Number of subjects: 100
Study 25240012 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, 400 mg) 1 h prior to LNG-IUS insertion
Number of subjects: 100
Study 23099972 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical/intracameral anesthesia (group 1)
Number of subjects: 46
Study 23099972 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia (group 2)
Number of subjects: 46
Study 20598832 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (ICBT)
Number of subjects: 236
Study 20598832 — intervention group
Group type: COMPARATOR
Intervention: Twelve‐Step Facilitation Therapy
Number of subjects: 236
Study 17903693 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg every day
Number of subjects: 174
Study 17903693 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg every day
Number of subjects: 174
Study 15649162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (30.000 KIU.kg(‐1) after induction, 30.000 KIU.kg(‐1) in pump prime, 30.000 KIU.kg(‐1) after weaning from bypass)
Number of subjects: 100
Study 15649162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (100 mg.kg(‐1) after induction, 100 mg.kg(‐1) in pump prime, 100 mg.kg(‐1) after weaning from bypass)
Number of subjects: 100
Study 15649162 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aprotinin and tranexamic acid (same dosages as above)
Number of subjects: 100
Study 15649162 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study 12237596 — intervention group
Group type: COMPARATOR
Intervention: 1-day intramuscular ceftriaxone regimen (50 mg/kg/day)
Number of subjects: 170
Study 12237596 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day intramuscular ceftriaxone regimen (50 mg/kg/day)
Number of subjects: 170
Study 10025832 — intervention group
Group type: EXPERIMENTAL
Intervention: 32P
Number of subjects: 31
Study 10025832 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr
Number of subjects: 31
Study 8862377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (IG)
Number of subjects: 838
Study 8862377 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 838
Study 1324238 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg/day
Number of subjects: 61
Study 1324238 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 500 mg/day
Number of subjects: 61
Study 6831819 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil (50 mg)
Number of subjects: 36
Study 6831819 — intervention group
Group type: EXPERIMENTAL
Intervention: propafenone (150 mg)
Number of subjects: 36
Study 6831819 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (10 mg)
Number of subjects: 36
Study 6831819 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (80 mg)
Number of subjects: 36
Study 6831819 — intervention group
Group type: EXPERIMENTAL
Intervention: quinidine (250 mg)
Number of subjects: 36
Study 6831819 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 30902369 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 132
Study 30902369 — intervention group
Group type: COMPARATOR
Intervention: Methylene blue dye
Number of subjects: 132
Study 27740721 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-MDI 50 mcg BID
Number of subjects: 0
Study 27740721 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-MDI 100 mcg BID
Number of subjects: 0
Study 27740721 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-MDI 200 mcg BID
Number of subjects: 0
Study 27740721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25857939 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching treatment with a prefabricated orthosis and stretching exercises
Number of subjects: 39